2007 Volume 23 Issue 2 Pages 95-100
The aim of the work presented here was to evaluate the efficacy and safety of a new regimen which combines weekly cisplatin-based chemotherapy and regional hyperthermia for the treatment of advanced hormone-refractory prostate cancer. Cisplatin (10 mg/body weight) was administered intravenously at weekly intervals one hour before regional hyperthermia, and was applied for a maximum of 10 cycles. Therapy was discontinued after the first 10 cycles in patients who responded, or in cases of stable disease, and was resumed as soon as any signs of progression were noted. Of the 15 patients evaluated, 6 were confirmed to have achieved a greater than 50% decrease in prostate specific antigen (PSA) levels (40.0%). The median response duration was 19.5 months, and the median time to progression was 9.0 months. Reduction of pain along with improvement in the quality of life were seen. Pain was reduced in 7 patients who were symptomatic at the beginning of the study. Of the 15 patients, 9 resumed therapy after the planned 10 original cycles of therapy. Of these, 9 received 10 mg of docetaxel/mg body weight. 4 patients had prostatic specific antigen (PSA) levels under 4 ng/ml (26.7%), and 2 patients exhibited stable disease. The regimen was well tolerated, and minor general fatigue (NCI-CTC grade1) was recognized in 3 patients, but no anemia or thrombocytopenia was observed. The results of this study suggest the feasibility and tolerability of using the combination of weekly cisplatin administration along with regional hyperthermia. This combined therapy led to a rapid and long lasting decrease in PSA levels and palliative responses in patients with advanced hormone-refractory prostate cancer.